From: Quality assessment of the guidelines for the management of malignant pleural effusions and ascites
Guideline ID | Organization | Country/area | Version | Topic | Grading system | Method |
---|---|---|---|---|---|---|
ATS, 2018 [5] | ATS/STS/STR | America | Original | Management of malignant pleural effusions | GRADE | EB |
ERS, 2018 [2] | ERS/EACTS | Europe | Original | Management of malignant pleural effusions | Unclear | EB |
BTS, 2010 [3] | BTS | Britain | Original | Management of malignant pleural effusions | Unclear | EB |
CGDTMPE, 2014 [4] | CGDTMPE | China | Original | Malignant pleural effusions | Unclear | CB |
CSCO, 2018 [1] | CSCO | China | Original | Administration of rmhTNF for malignant ascites | Unclear | EB |
CTS, 2009 [6] | CTS | China | Original | Respiratory diseases | Unclear | CB |
JSPM1, 2016 [7] | JSPM | Japan | Original | Parenteral fluid management for terminal cancer patients | GRADE | CB |
JSPM2, 2016 [8] | JSPM | Japan | Original | Treatment recommendations for respiratory symptoms in cancer patients | GRADE | EB |
JSPM, 2019 [9] | JSPM | Japan | Original | Gastrointestinal symptoms in cancer patients | GRADE | EB |